What is he best known for?
The fields of study he is best known for:
Henry A. Erlich mainly focuses on Genetics, Human leukocyte antigen, Immunology, Haplotype and Allele.
His studies in Genotype, Linkage disequilibrium, Locus, Allele frequency and Polymerase chain reaction are all subfields of Genetics research.
The various areas that Henry A. Erlich examines in his Human leukocyte antigen study include Major histocompatibility complex, Immune system, Genome and Genetic variation.
His biological study spans a wide range of topics, including Internal medicine, Cohort study, Prospective cohort study, Cohort and Coeliac disease.
His Haplotype research is multidisciplinary, incorporating perspectives in Odds ratio, Proband, Genetic association and Genetic predisposition.
His Allele research is multidisciplinary, incorporating elements of Myeloid and Genetic marker.
His most cited work include:
- Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia (8015 citations)
- Process for amplifying, detecting, and/or-cloning nucleic acid sequences (5521 citations)
- Specific Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction (2736 citations)
What are the main themes of his work throughout his whole career to date?
Henry A. Erlich focuses on Genetics, Human leukocyte antigen, Allele, Haplotype and Immunology.
The Genetics study which covers Type 1 diabetes that intersects with Internal medicine.
In his study, DNA sequencing is inextricably linked to Amplicon, which falls within the broad field of Human leukocyte antigen.
The Allele study combines topics in areas such as Evolutionary biology, Genetic predisposition and Phylogenetic tree.
His research investigates the connection with Haplotype and areas like Single-nucleotide polymorphism which intersect with concerns in Candidate gene.
His study ties his expertise on Islet together with the subject of Immunology.
He most often published in these fields:
- Genetics (66.89%)
- Human leukocyte antigen (48.99%)
- Allele (49.22%)
What were the highlights of his more recent work (between 2009-2021)?
- Genetics (66.89%)
- Human leukocyte antigen (48.99%)
- Allele (49.22%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Genetics, Human leukocyte antigen, Allele, Immunology and Genotype.
He combines topics linked to Type 1 diabetes with his work on Genetics.
The study incorporates disciplines such as Odds ratio, Genetic predisposition, Amplicon, Genetic variation and Transplantation in addition to Human leukocyte antigen.
His Allele research integrates issues from Single-nucleotide polymorphism and Locus.
The concepts of his Immunology study are interwoven with issues in Internal medicine and Cohort.
As a part of the same scientific family, he mostly works in the field of Haplotype, focusing on Genetic association and, on occasion, Peptide binding.
Between 2009 and 2021, his most popular works were:
- Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. (386 citations)
- Genetics of Type 1 Diabetes: What's Next? (224 citations)
- Genetics of Type 1 Diabetes (207 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Genetics, Human leukocyte antigen, Type 1 diabetes, Immunology and Haplotype.
Genetics is a component of his Allele, Genome-wide association study, Genotyping, Genome and Sequence analysis studies.
His work deals with themes such as Linkage disequilibrium and Locus, which intersect with Human leukocyte antigen.
His research integrates issues of Disease and Genotype in his study of Type 1 diabetes.
The study of Immunology is intertwined with the study of Internal medicine in a number of ways.
Many of his studies involve connections with topics such as Major histocompatibility complex and Haplotype.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
